CGON

In the past six months (April-October 2026), CG Oncology reported a Q1 2026 loss but topped revenue estimates in May 2026, and a Q2 2026 loss in August 2026, missing estimates, though the stock gained 3.36% post-report. Pivotal Phase 3 BOND-003 Cohort C study results were published in The Lancet Oncology in July 2026. The company anticipates topline data from its PIVOT-006 Phase 3 trial soon and first results from CORE-008 Cohort CX Phase 2 trial in the first half of 2026. CGON's stock reached an all-time high of $80.97 in the past year but decreased by 15.01% in the past month as of September 26, 2026. A shareholder litigation law firm, Kuehn Law, announced an investigation in August 2026, and insider selling activity was reported in September 2026.